Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2018 Congress

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3252 - First-line Treatment of Desmoid Tumor: Systemic Therapy versus Upfront Surgery

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy;  Surgical Oncology

Tumour Site

Sarcoma

Presenters

Juliana Souza

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

J.C.E.S.O.D. Souza, H.M. Lourenço, G. Mendes

Author affiliations

  • Oncology Department, INCA - Instituto Nacional de Cancer, 20231-050 - Rio de Janeiro/BR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Login

Abstract 3252

Background

Desmoid tumor (DT) is a rare and locally invasive proliferative disease. The standard first-line treatment used to be radical surgical resection. However, during recent years it has been debated whether to offer an aggressive and morbidity treatment to a potentially indolent tumor. Desmoid tumor has uncertain behavior, some are aggressive cases, others indolent and there are some reports of spontaneous involution. Nowadays, the guidelines suggest to watch and wait before offering an aggressive treatment, and avoiding the surgical treatment. But in our experience patients had less morbidity and disease progression with a surgical approach.

Methods

Patients with histological diagnosis of DT and treated at INCA between January 1998 and December 2015 were identified and their medical records were analyzed.

Results

Of 191 patients evaluated, there were 137 females (71.2%). The median age at diagnosis was 34 years (range:17.79-76.96y). Tumor locations were: thoracoabdominal wall (n = 100, 52.3%), extremities (n = 53,27.7%), abdominal cavity (n = 26; 13.6%), and head and neck (n = 12, 6.2%). Tumor sizes were documented in 152 cases (79.5%) and ranged from 1 cm to 37 cm (median, 10 cm). Twenty-seven pts (14.1%) received systemic therapy (ST) (n = 5 vinblastine and methotrexate; n = 22 tamoxifen) and 164 pts (85.8%) were submitted to surgery (4pts received adjuvant tamoxifen) as first-line treatment. There was no difference between gender (p = 0.86), tumor location (p = 0.30), or tumor size (p = 0.53) when choosing first-line treatment. The odds of severe morbidity were 2.13 higher with ST than with upfront surgery. Four pts were submitted to surgery after systemic first-line treatment. After a median follow-up of 71 months, there was significantly more disease progression in the ST group (17pts – 62.9%) than in the surgery group (55 pts – 33.5%) (p = 0.005), and they received more subsequent treatment (p = 0,01). There were 2 deaths in the ST group and 9 deaths in the surgery group, with 10-year survival of 93.2% and 92%, respectively.

Conclusions

DT is an indolent disease but has the propensity for locally invasive growth and recurrence. Although ST is a less aggressive treatment, it was associated with higher severe morbidity, more disease progression, and more subsequent treatment in this trial.

Clinical trial identification

Legal entity responsible for the study

INCA.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

4697 - Genetic signatures always suggest undertreatment? Experience with PAM51

Presenter: Carolina Sales

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.